Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study

Respiratory Medicine

Volumn 109, Issue 7, 2015, Pages 904-913

  Harari, S ^a   Caminati, A ^a   Albera, C ^b   Vancheri, C ^c   Poletti, V ^d   Pesci, A ^e   Luppi, F ^f   Saltini, C ^g   Agostini, C ^h   Bargagli, E ⁱ   Sebastiani, A ^j   Sanduzzi, A ^k   Giunta, V ^a   Della Porta, R ^l   Bandelli, G P ^b   Puglisi, S ^c   Tomassetti, S ^d   Biffi, A ^e   Cerri, S ^f   Mari, A ^g   Cinetto, F ^h   Tirelli, F ⁱ   Farinelli, G ^j   Bocchino, M ^k   Specchia, C ^m,n   Confalonieri, M ^l   more..

^a IRCCS   (Italy)

^b San Luigi Gonzaga University Hospital   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY HOSPITAL OF SIENA   (Italy)

^j SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^m UNIVERSITY OF BRESCIA   (Italy)

ⁿ IRCCS MULTIMEDICA   (Italy)

more..

Author keywords

IPF; Pirfenidone; Therapy

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; ATTENUATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HISTOLOGY; HUMAN; LUNG CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CLINICAL TRIAL; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; ITALY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; ITALY; MALE; PYRIDONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84930759119     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.04.010     Document Type: Article

References (20)

1. G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, and K.K. Brown An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 2011 788 824
2. A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, and K. Nakata Double-blind, placebo-controlled trial on pirfenidonein patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 171 2005 1040 1047
3. H. Taniguchi, M. Ebina, Y. Kondoh, T. Oqura, A. Azuma, and M. Suga Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 35 2010 821 829
4. P.W. Noble, C. Albera, W.Z. Bradford, U. Costabel, M.K. Glassberg, and D. Kardatzke Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 2011 1760 1769
5. T.E. King Jr., W.Z. Bradford, S. Castro-Bernardini, E.A. Fagan, I. Glaspole, and M.K. Glassberg A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2014 2083 2092
6. L. Richeldi, R.M. du Bois, G. Raghu, A. Azuma, K.K. Brown, and U. Costabel Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 2014 2071 2082
7. G. Raghu, K.J. Anstrom, T.E.J.R. King, J.A. Lasky, F.J. Martinez, and The Idiopathic Pulmonary Fibrosis Clinical Research Network Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis N Engl J Med 24 366 2012 1968 1977
8. L. Richeldi, H.R. Davies, P. Spagnolo, and F. Luppi Corticosteroids for idiopathic pulmonary fibrosis Art. N. CD002880 Cochraine Database Syst Rev 3 2003 10.1002/14651858 CD002880
9. B. Ley, C.J. Ryerson, E. Wittinghoff, J.H. Ryu, S. Tomasetti, and J.S. Lee A multidimensional index and staging system for idiopathic pulmonary fibrosis Ann Intern Med 156 2012 684 691
10. R. Okuda, E. Hagiwara, T. Baba, H. Kitamura, T. Kato, and T. Oqura Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice Respir Med 107 2013 1431 1437
11. U. Oltmanns, N. Khan, K. Palmowski, A. Träger, H. Wenz, and C.P. Heussel Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases Respiration 88 2014 199 207
12. N. Chaudhuri, A. Duck, R. Frank, J. Holme, and C. Leonard Reald world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis Respir Med 108 2014 224 226
13. M. Demedts, J. Behr, R. Buhl, U. Costabel, R. Dekhuijzen, and H.M. Jansen IFIGENIA study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis N Engl J Med 24 353 2005 2229 2242
14. F.J. Martinez, G. Raghu, M. Schwarz, G.B. Toews, G. Hunninghake, and J. Zibrak Randomized trial of acetylcisteine in idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis clinical research Network N Engl J Med 370 2014 2093 2101
15. R.M. du Bois, D. Weycker, C. Albera, W.Z. Bradford, U. Costabel, and A. Kartashov Forced vital capacity in patients with idiopathic pulmonary fibrosis. Test properties and minimal clinically important difference Am J Respir Crit Care Med 184 2011 1382 1389
16. R.M. du Bois, S.D. Nathan, L. Richeldi, M.I. Schwarz, and P.W. Noble Idiopathic pulmonary fibrosis. Lung function is a clinically mainingful endpoint for phase III trials Am J Respir Crit Care Med 186 2012 712 715
17. A.U. Wells, J. Behr, U. Costabel, V. Cottin, V. Poletti, and L. Richeldi Morality as primary end-point in IPF treatment trials: the best is the enemy of the good Thorax 67 2012 938 940
18. S.L. Schmidt, N. Tayob, M.K. Han, C. Zappala, D. Kervitsky, and S. Murray Predicting pulmonary fibrosis disease course from past trends in pulmonary function Chest 145 2014 579 585
19. S.D. Nathan, and K.C. Meyer IPF clinical trial design and endpoints Curr Opin Pulm Med 20 2014 463 471
20. B. Loeh, F. Drakopanagiotakis, G.P. Bandelli, D. von der Beck, S. Tello, and E. Cordani Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 191 2015 110 113